Related Experiment Video
Updated: Nov 3, 2025

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
Published on: January 16, 2019
Epidemiology, prognosis and management of potassium disorders in Covid-19
Maryam Noori1, Seyed A Nejadghaderi2,3, Mark J M Sullman4,5
1School of Medicine, Student Research Committee, Iran University of Medical Sciences, Tehran, Iran.
Insights
Potassium disorders like hypokalemia and hyperkalemia are common in COVID-19 patients, impacting cardiac outcomes and survival. Managing these electrolyte imbalances is crucial for improving prognosis in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Area of Science:
- Infectious Diseases
- Cardiology
- Nephrology
- Critical Care Medicine
Background:
- Coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), presents a global health crisis.
- Electrolyte abnormalities, particularly potassium disorders, are frequently observed in COVID-19 patients.
- Deviations in potassium levels are associated with increased risks of adverse outcomes and mortality.
Purpose of the Study:
- To review the epidemiology of potassium disorders in COVID-19 patients.
- To elucidate the mechanisms by which hypokalemia and hyperkalemia affect cardiac outcomes and prognosis.
- To highlight key management considerations for potassium imbalances in COVID-19.
Main Methods:
- Pooled analysis of COVID-19 patient data.
- Review of existing literature on electrolyte disturbances and cardiovascular complications.
- Epidemiological assessment of hypokalemia and hyperkalemia prevalence.
Main Results:
- Hypokalemia observed in 24.3% of COVID-19 patients.
- Hyperkalemia observed in 4.15% of COVID-19 patients.
- Potassium level deviations correlate with poorer prognosis and increased mortality.
Conclusions:
- Potassium disorders are significant complications of COVID-19.
- These imbalances can severely impact cardiac function and patient survival.
- Effective management strategies for hypokalemia and hyperkalemia are essential for COVID-19 patient care.
Abstract:
Coronavirus disease (Covid-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is currently the largest health crisis facing most countries. Several factors have been linked with a poor prognosis for this disease, including demographic factors, pre-existing comorbidities and laboratory parameters such as white blood cell count, D-dimer, C-reactive protein, albumin, lactate dehydrogenase, creatinine and electrolytes. Electrolyte abnormalities particularly potassium disorders are common among Covid-19 patients. Based on our pooled analysis, hypokalemia and hyperkalemia occur in 24.3% and 4.15% of Covid-19 patients, respectively. Potassium level deviation from the normal range may increase the chances of unfavorable outcomes and even death. Therefore, this article reviewed the epidemiology of potassium disorders and explained how hypokalemia and hyperkalemia are capable of deteriorating cardiac outcomes and the prognosis of Covid-19 for infected patients. The article finishes by highlighting some important considerations in the management of hypokalemia and hyperkalemia in these patients.
Related Concept Videos
Acute Kidney Injury V: Interprofessional Care
Antihypertensive Drugs: Potassium-Sparing Diuretics
Chronic Kidney Disease IV: Nursing Management
Acute Kidney Injury VI: Nursing Management
Chronic Kidney Disease III: Interprofessional Care
Acute Kidney Injury IV: Diagnostic Studies and Prevention

